Evidence map›Paper›PMID 33489440›Full record

ArticleAmerican journal of blood research2020

The prognostic factors and efficacy of induction chemotherapy in elderly patients with acute myeloid leukemia.

Jianping Mao, Wenliang Gao, Lianguo Xue, Lidong Zhao, Lei Miao, Tao Jia, Yuanxin Zhu, Ying Wang, Lijuan Meng, Juan Wang

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of blood research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 77% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jianping MaoDepartment of Hematology, The First People's Hospital of Lianyungang City, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The Affiliated Hospital of Kangda College of Nanjing Medical University, Lianyungang Clinical College of Nanjing Medical University Lianyungang, China.
Wenliang GaoDepartment of Internal Medicine, The Second Children and Women's Health Care of Jinan City Jinan, China.
Lianguo XueDepartment of Hematology, The First People's Hospital of Lianyungang City, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The Affiliated Hospital of Kangda College of Nanjing Medical University, Lianyungang Clinical College of Nanjing Medical University Lianyungang, China.
Lidong ZhaoDepartment of Hematology, The First People's Hospital of Lianyungang City, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The Affiliated Hospital of Kangda College of Nanjing Medical University, Lianyungang Clinical College of Nanjing Medical University Lianyungang, China.
Lei MiaoDepartment of Hematology, The First People's Hospital of Lianyungang City, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The Affiliated Hospital of Kangda College of Nanjing Medical University, Lianyungang Clinical College of Nanjing Medical University Lianyungang, China.
Tao JiaDepartment of Hematology, The First People's Hospital of Lianyungang City, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The Affiliated Hospital of Kangda College of Nanjing Medical University, Lianyungang Clinical College of Nanjing Medical University Lianyungang, China.
Yuanxin ZhuDepartment of Hematology, The First People's Hospital of Lianyungang City, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The Affiliated Hospital of Kangda College of Nanjing Medical University, Lianyungang Clinical College of Nanjing Medical University Lianyungang, China.
Ying WangDepartment of Hematology, The First People's Hospital of Lianyungang City, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The Affiliated Hospital of Kangda College of Nanjing Medical University, Lianyungang Clinical College of Nanjing Medical University Lianyungang, China.
Lijuan MengDepartment of Geriatric Oncology, The First Affiliated Hospital with Nanjing Medical University Nanjing, China.
Juan WangDepartment of Pediatrics, The First People's Hospital of Lianyungang City Lianyungang, China.
Nanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveAcute myeloid leukemia (AML) is the most common form of hematological malignancy in adults. We aimed to investigate the efficacy of different treatment measures and prognostic factors for elderly patients with AML.

methodsThe clinical data of 65 newly diagnosed elderly patients with AML were retrospectively analyzed. Among them, 45 patients received induction chemotherapy including standard cytarabine regimen (n = 21) and low dose cytarabine regimen (n = 24), and 20 patients received palliative treatment. The efficacy and prognosis were compared between the groups.

resultsThere were no statistical differences in complete remission, overall survival and the 6-month disease-free survival rates between standard cytarabine group and low dose cytarabine group (

conclusionsThe induction chemotherapy did not increase the early mortality. The low dose cytarabine regimen can be used as the first-line choice for elderly acute myeloid leukemia patients who are not suitable for intensive chemotherapy.

Indexed as

Acute myeloid leukemiaelderlyprognosistreatment

Identifiers

PMID33489440
PMCPMC7811900
OpenAlexW3125459591

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.